Reading Time: 3 minutes

Data From WATER, WATER II and Single-Center Studies of PROCEPT
BioRobotics’ Aquablation Therapy Will Be Revealed

REDWOOD SHORES, Calif.–(BUSINESS WIRE)–lt;a href=”” target=”_blank”gt;#AUA2019lt;/agt;–PROCEPT®
announced today that two pivotal studies and one
all-comers commercial series featuring the company’s Aquablation® therapy for
the treatment of benign prostatic hyperplasia (BPH) will be presented at
the American Urological Association (AUA) Annual Meeting at McCormick
Place in Chicago, May 3 – 6, 2019. Aquablation therapy, delivered by the
AquaBeam® Robotic System, is the only FDA cleared, autonomous robot for

PD10-12 “WATER II: Aquablation Therapy for Benign Prostatic
Hyperplasia in Men with Large Prostates (80-150 mL): One-Year Safety and
Efficacy Results”

May 3, 11:20 – 11:30 a.m.
data from the WATER II Study (Waterjet Ablation Therapy
for Endoscopic Resection of Prostate Tissue), evaluating
the safety and efficacy of Aquablation therapy in 101 men with large
prostates 80 to 150 milliliters (mL) in size, will be presented by Naeem
Bhojani, M.D., associate professor at the Université de Montréal,
Montréal, Canada. The podium session PD10-12, titled “WATER II:
Aquablation Therapy for Benign Prostatic Hyperplasia in Men with Large
Prostates (80-150 mL): One-Year Safety and Efficacy Results,” follows
the release of WATER II six-month data at the European Association of
Urology Annual (EAU) Congress in March, which determined that
Aquablation therapy is a safe surgical alternative for treating men with
large prostates, where surgical options are limited.

MP45-11 “The WATER Study Clinical Results – Results at Two Years and
Urodynamic Findings”

May 4, 3:30 – 5:30 p.m.
follow-up data from the WATER Study, which compared the safety and
efficacy of Aquablation therapy to the most common BPH surgical method,
transurethral resection of the prostate (TURP), in 181 men with
prostates between 30 and 80 mL in size, will be presented by Peter
Gilling, M.D., co-principal investigator and professor of surgery at the
University of Auckland, Bay of Plenty Clinical School Tauranga, New
Zealand. The moderated poster MP45-11 titled, “The WATER Study Clinical
Results – Results at Two Years and Urodynamic Findings,” will build on
WATER Study one-year data featured at AUA 2018, which demonstrated
similar durable outcomes at one year compared to TURP, a low retreatment
rate and symptom improvement scores comparable to other resective
techniques. Dr. Gilling recently received two awards at the USANZ annual
conference related to this data set.

MP45-10 “Real-life Data From 180 Consecutive Patients Undergoing
Aquablation of the Prostate”

May 4, 3:30 – 5:30 p.m.
third study, “Real-life Data From 180 Consecutive Patients Undergoing
Aquablation of the Prostate,” will be presented by Prof. Thorsten Bach,
chief physician in urology at Asklepios Hospital Harburg in Hamburg,
Germany. The moderated poster MP45-10 will highlight single-center
results of a consecutive, 180-patient cohort treated with Aquablation
therapy between September 2017 and June 2018.

“These clinical presentations validate the durability, superior safety
and gold standard-like effectiveness of Aquablation therapy in a broad
range of prostates along with a large data set of real-world experience.
We are thrilled to present this robust set of clinical data at AUA in
Chicago,” said Nikolai Aljuri, Ph.D., PROCEPT BioRobotics, president and
chief executive officer. “BPH is a condition that affects millions of
men worldwide, and yet relatively few patients elect to treat their BPH
with surgery due to potential complications. With Aquablation therapy,
we offer patients a heat-free, minimally invasive and robotically
controlled treatment option that helps alleviate their concerns and
provides safe and effective symptom relief.”

For more information about Aquablation therapy, visit PROCEPT
BioRobotics at AUA Booth #4027 at McCormick Place.

About PROCEPT BioRobotics
Based in Silicon Valley, PROCEPT
BioRobotics is a privately-held surgical robotics company enabling
better patient care by developing transformative solutions in urology.
The company offers the world’s first commercially available minimally
invasive surgical robot providing autonomous tissue removal to safely
and effectively treat BPH. Aquablation therapy, delivered by the
AquaBeam® Robotic System, combines the clarity of real-time,
multi-dimensional imaging, autonomous robotics and heat-free waterjet
ablation for targeted, controlled, and immediate removal of prostate
tissue for the treatment of lower urinary tract symptoms (LUTS) caused
by BPH. The therapy offers predictable and reproducible outcomes,
independent of prostate anatomy, prostate size or surgeon experience.
For more information, visit

Important Safety Information
All surgical treatments have
inherent and associated side effects. The most common side effects are
mild and transient, and may include mild pain or difficulty when
urinating, discomfort in the pelvis, blood in the urine, inability to
empty the bladder or a frequent and/or urgent need to urinate, and
bladder or urinary tract infection. Other risks include ejaculatory
dysfunction and a low risk of injury to the urethra or rectum where the
devices gain access to the body for treatment. For more information
about potential side effects and risks associated with Aquablation
therapy, speak with your urologist or surgeon.
No claim is made
that the AQUABEAM Robotic System will cure any medical condition, or
entirely eliminate the diseased entity. Repeated treatment or
alternative therapies may sometimes be required.


Diana Soltesz
Nobles Global Communications
[email protected]